Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study
Journal of Clinical Lipidology · 2026-06 · 20 (6) · e113
DOI: 10.1016/j.jacl.2026.05.174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-06. Verfasst von Geoffroy Napon und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Napon, G., Roy, S., Jain, V., Igbinigie, I., Rayapureddi, K., Aiyer, A., & Gupta, T. (2026). Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study. Journal of Clinical Lipidology, 20(6), e113. https://doi.org/10.1016/j.jacl.2026.05.174
Vancouver
Napon G, Roy S, Jain V, Igbinigie I, Rayapureddi K, Aiyer A, et al. Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study. Journal of Clinical Lipidology. 2026;20(6):e113. doi:10.1016/j.jacl.2026.05.174
BibTeX
@article{Napon2026,
author = {Napon, Geoffroy and Roy, Shubha and Jain, Varun and Igbinigie, Ikponmwosa and Rayapureddi, Karthik and Aiyer, Aishwarya and Gupta, Tejasva},
title = {Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {6},
pages = {e113},
doi = {10.1016/j.jacl.2026.05.174}
}
EUVIMED